A novel PET tracer, [18F]XW-032, was developed via ruthenium-mediated deoxyfluorination and effectively visualized regional IDO1 heterogeneity in the AD brain, positioning it as a potent molecular tool for early AD diagnosis and for monitoring the efficacy of IDO1-targeted therapeutic interventions.
Hua Cheng, Nilay S. Narayan, Yong-Le Wang et al.· Materials Today Bio· 0 citations
Treatment of AD patient-derived hiPSC glia cells including microglia and astrocytes and neuropathic pain mice with 22 led to suppression of NLRP3 expression and decreased pain and pain-like behavior, supporting the translational promise of this compound and analogs from this chemotype.
Yi-Ming Xu, J. Namme, Liuyue Yang et al.· European journal of medicina...· 0 citations
The current understanding of HDAC6-mediated SG regulation in AD is highlighted, critical knowledge gaps are identified, and the therapeutic potential of selective HDAC6 inhibition in modulating SG pathology and neuroinflammation is discussed.
Emona Jagaselvan, Prasenjit Mondal, Can Zhang· ACS Chemical Neuroscience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.